Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

New Understanding of Receptor Regulation Suggests Target for New Drugs

By BiotechDaily International staff writers
Posted on 09 Jan 2013
A study leading to improved understanding of G-protein coupled receptor regulation suggests a new set of targets for designing drugs to more effectively regulate this medically important family of receptors.

More than one-third of drugs on the market directly or indirectly regulate G protein-coupled receptors (GPCRs). Some indirect drugs trigger beta arrestins that downregulate activated GPCRs mainly by causing the receptors to be removed from the cell surface to be subsequently recycled or, via ubiquitination, degraded. The natural action of beta arrestins lowers the cell surface concentration of GPCRs and so can interfere with drugs designed to directly target GPCRs, in some cases leading to drug tolerance in patients and a need for using higher doses.

The current study, led by principal investigator Carlos E. Alvarez, PhD, at Nationwide Children's Hospital (Columbus, OH, USA), identified related GPCR regulatory roles by another subfamily of arrestins, the “alpha arrestins,” recently discovered by Dr. Alvarez’s laboratory. Using biochemical and imaging approaches, the researchers now found that alpha arrestins respond to ligand-bound receptor activation, and recruit enzymes that chemically modify the receptor to initiate aspects of down-regulation. Time course studies showed that these effects occur in the first 1-5 minutes after ligand activation, the same time frame that beta arrestins are known to trigger receptor downregulation. Using coimmunoprecipitation and co-localization methods, the researchers were also the first to find strong evidence suggesting that alpha arrestins function coordinately with beta arrestins.

"Our findings suggest that alpha arrestins, like beta arrestins, are ubiquitous regulators of G-protein coupled receptor signaling," said Dr. Alvarez. A major effort in current pharmacology is to develop drugs with functional selectivity that target either G protein or beta arrestin signaling effects. Dr. Alvarez foresees alpha arrestins becoming important in refining such efforts. "Just as has been discovered with beta blockers and beta arrestin, I expect we'll find drugs that also have significant alpha arrestin effects," said Dr. Alvarez.

The study was published online December 7, 2012, in the journal PLoS One.

Related Links:
Nationwide Children's Hospital




comments powered by Disqus

Channels

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.